Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Seattle Genetics Inc. (SGEN), Cerus Corporation (CERS): Baker Bros. Advisors’ Latest Moves

Baker Bros. Advisors, the fund managed by Julian and Felix Baker disclosed changes in two of its activist positions last Thursday. The firm continued to boost its exposure to Seattle Genetics, Inc. (NASDAQ:SGEN) by approximately 3.6%, to 25.2 million shares of common stock, and trimmed its stake in Cerus Corporation (NASDAQ:CERS) by 1.8%, to 11.7 million shares of common stock. These stakes represent 20.3% and 15.0% of the companies’ shares outstanding, respectively.

Baker Bros. Advisors is a New York City-based hedge fund founded in the year 2000. The firm typically invests in the healthcare segment, which comprises 99.8% of its third quarter equity portfolio, worth about $7.9 billion.

Felix Baker - Baker Bros.

Seattle Genetics, Inc. (NASDAQ:SGEN) is a $4.23 billion market cap biotechnology company that develops and commercializes monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. The Baker brothers have been augmenting their wage on this company for a while now. Since the end of the third quarter, the fund already increased its exposure once. On this second occasion, it took its stake to 25.22 million shares, as the company’s pipeline continues to develop. The purchases were made for prices ranging from $32.56 per share to $34.95 per share.

Other major institutional investors betting on Seattle Genetics, Inc. (NASDAQ:SGEN) are Peter Kolchinsky’s RA Capital Management and Pasco Alfaro and Richard Tumure’s Miura Global Management. Both these funds started new positions in the company over the third quarter, with 5.38 million shares and 4.16 million shares, respectively.

Cerus Corporation (NASDAQ:CERS) is a biomedical products company with a market cap of $363.1 million. It focuses on commercializing the INTERCEPT Blood System to enhance blood safety. As the stock price escalated over the past few days, Baker Bros. Advisors decided to sell some of its stock, reducing its stake to a 15.0% of the company. With such a large involvement in the company, one should not interpret this one as a bearish move, but rather as a chance of making some money out of their investment. In fact, despite this reduction, the fund continues to stand as the largest institutional investor, amongst those we track.

Also betting big on Cerus Corporation (NASDAQ:CERS) are Samuel Isaly and Chuck Royce. Both of them upped their stakes over the third quarter, by 70% and 2%, respectively, and now own 7.18 million shares and 3.76 million shares, correspondingly.

Disclosure: Javier Hasse holds no positions in any stocks or funds mentioned

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
This is a FREE report from Insider Monkey. Credit Card is NOT required.